Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targets for Drug Action: Overview

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults.

Journal of thrombosis and haemostasis : JTH·2018

Same author

Acute coronary syndrome remodels the antiplatelet aggregation properties of HDL particle subclasses.

Journal of thrombosis and haemostasis : JTH·2018

Same author

Mass Assays to Quantify Bioactive PtdIns3P and PtdIns5P During Autophagic Responses.

Methods in enzymology·2017

Same author

Cdc42-dependent F-actin dynamics drive structuration of the demarcation membrane system in megakaryocytes.

Journal of thrombosis and haemostasis : JTH·2016

Same author

ATP-binding cassette transporter 1 (ABCA1) deficiency decreases platelet reactivity and reduces thromboxane A2 production independently of hematopoietic ABCA1.

Journal of thrombosis and haemostasis : JTH·2016

Same author

A confocal-based morphometric analysis shows a functional crosstalk between the actin filament system and microtubules in thrombin-stimulated platelets.

Journal of thrombosis and haemostasis : JTH·2012

Search research articles

Related Experiment Video

Updated: May 28, 2026

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Targeted drug therapy: the platelet side.

T Lhermusier¹, J Van Rothem, C Garcia

¹Inserm, U1048 and Université Toulouse III Paul Sabatier, I2MC, 31024 Toulouse Cedex 03, France.

|October 7, 2011

Summary

Targeted cancer therapies, especially kinase inhibitors, can affect platelet activation. Understanding these effects is crucial for clinical practice and developing new antiplatelet strategies.

More Related Videos

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

Related Experiment Videos

Last Updated: May 28, 2026

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

Area of Science:

Oncology
Hematology
Pharmacology

Background:

Targeted therapies, particularly kinase inhibitors, represent a significant advancement in cancer treatment.
These drugs target critical intracellular signaling proteins, many of which are also involved in platelet activation pathways.
The widespread expression of these targets across cell types necessitates an understanding of their impact on platelets.

Purpose of the Study:

To review major platelet signaling pathways potentially affected by targeted cancer therapies.
To discuss the clinical implications of these drug effects on platelet function.
To explore opportunities for developing novel antiplatelet strategies based on this knowledge.

Main Methods:

Literature review of platelet signaling pathways.
Analysis of existing data on targeted therapies and their known effects.
Discussion of clinical case studies and physiological relevance.

Main Results:

Identified key platelet signaling pathways (e.g., PI3K/Akt, MAPK) that are common targets for cancer drugs.
Highlighted potential for both pro- and anti-thrombotic effects of targeted therapies on platelets.
Emphasized the need for monitoring platelet function in patients receiving these treatments.

Conclusions:

Targeted cancer therapies can significantly impact platelet activation, with potential clinical consequences.
Further research into these interactions can lead to improved patient management and novel antiplatelet drug development.
Integrating knowledge of platelet biology with targeted therapy mechanisms is essential for future cancer care.